Device sales boost J&J's Q1 earnings

Johnson & Johnson reported better-than-expected first-quarter earnings, with earnings of $4.53 billion, or $1.62 per share, on revenue of $15.63 billion. And the pharma giant has its medical device business to thank for the results. Device and diagnostics sales totaled $6.2 billion for the first quarter represented--a 12.5 percent jump over last year. Domestic sales increased 8.8 percent, while international sales increased 15.9 percent.                                                               

Four areas are responsible for the growth in sales: Ethicon's surgical care products; DePuy's orthopaedic joint reconstruction and sports medicine businesses; Ethicon Endo-Surgery's minimally invasive products and Advanced Sterilization Products' infection prevention solutions; and Ortho-Clinical Diagnostics' professional products. The higher sales in these areas helped offset slower sales of Cordis' drug-eluting stent, as well as revenue declines for its prescription drugs and consumer products.

- see J&J's release
- read the MarketWatch article for more

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.